What drove the intraday move in EVE.SW stock today?

Volume spikes and a recent earnings announcement on 25 Feb 2026 lifted EVE.SW stock. Technical momentum and short-term buying interest behind the 50-day average helped push price to CHF 0.90.

What are realistic price targets for EVE.SW stock?

Near-term target: CHF 1.20. 12-month model target: CHF 1.84. Three-year model target: CHF 2.48. These imply upside of 33.33% to 175.56% from CHF 0.90 and are model projections, not guarantees.

How does EvoNext’s valuation compare to the Healthcare sector?

EVE.SW shows negative EPS and a negative PE, while Healthcare peers average PE is CHF 35.67. EvoNext’s PB of 1.12 and cash per share CHF 0.87 offset some valuation concerns but reflect small-scale operations.

What are the main risks for EVE.SW investors?

Key risks include development or licensing setbacks, thin trading liquidity, and reliance on external funding. The company’s small market cap increases price volatility in stress scenarios.

CH Stocks

EvoNext (EVE.SW) SIX CHF 0.90 intraday 26 Feb 2026: momentum, check targets

ByHuzaifa Zahoor February 26, 2026

EVE.SW stock opened higher intraday on 26 Feb 2026 and trades at CHF 0.90 on the SIX exchange in Switzerland. Volume is 15,085.00 shares, above the 50-day average of 7,362.00. The move follows a 21.25% one-month gain and a recent earnings announcement on 25 Feb 2026. We track price action, technical momentum, and valuation for EvoNext Holdings S.A. as investors evaluate near-term targets and risks.